Overview

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Status:
Completed
Trial end date:
2016-04-13
Target enrollment:
Participant gender:
Summary
This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of [14C]ACP-196.
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib